Form 4: Kronos Bio Director's Stock Options Cancelled for No Cash Consideration Following Concentra Biosciences Merger

A recent SEC Form 4 filing reveals that Kronos Bio, Inc. Director Katherine V. Stultz disposed of over 100,000 stock options as part of the company's acquisition by Concentra Biosciences, with options having an exercise price above the cash offer cancelled for no cash consideration.

Summary

• The filing is a Form 4, reporting changes in beneficial ownership for Katherine V. Stultz, a Director of Kronos Bio, Inc.
• The changes are a result of the Agreement and Plan of Merger, dated May 1, 2025, between Kronos Bio, Inc., Concentra Biosciences, LLC, and Concentra Merger Sub IV, Inc.
• A tender offer for Kronos Bio shares was completed on June 18, 2025, at an offer price of $0.57 per share in cash plus one non-transferable contractual contingent value right (CVR).
• Following the tender offer, Merger Sub merged into Kronos Bio, making Kronos Bio a wholly-owned subsidiary of Concentra Biosciences.
• Immediately prior to the merger, all outstanding stock options became fully vested and exercisable.
• Options not exercised were cancelled and converted into a right to receive cash (if the exercise price was below the cash offer price) and one CVR per underlying share.
• Options with an exercise price equal to or greater than the $0.57 cash amount were cancelled for no cash consideration.
• Katherine V. Stultz disposed of 68,000 stock options with an exercise price of $1.29, 7,079 options at $1.48, and 34,000 options at $0.95, all of which were cancelled for no cash consideration as their exercise prices exceeded the $0.57 cash offer.

Sentiment

Score: 3

Explanation: The sentiment is negative for the option holder as their options were cancelled for no cash consideration, indicating a loss on those specific holdings relative to the cash offer. While the merger itself provides liquidity for shareholders, the specific outcome for these options is unfavorable.

Positives

• The merger completion indicates a successful acquisition for Kronos Bio shareholders, who received $0.57 per share in cash plus a CVR.
• All outstanding stock options became fully vested and exercisable immediately prior to the merger, providing liquidity for option holders.

Negatives

• Stock options with exercise prices above the $0.57 cash offer price, including all 109,079 options held by Katherine V. Stultz detailed in this filing, were cancelled for no cash consideration, meaning these options were 'out of the money' relative to the cash component of the offer.
• The CVRs are non-transferable, limiting their liquidity for recipients.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on future events, as they are non-transferable and their ultimate value is not guaranteed.

Future Outlook

The document indicates that Kronos Bio, Inc. has become a wholly-owned subsidiary of Concentra Biosciences, LLC, following the completion of the merger. The future outlook for former Kronos Bio shareholders now includes the potential value of non-transferable Contingent Value Rights (CVRs), which are dependent on future events.

Industry Context

This filing reflects a consolidation event within the biotechnology or pharmaceutical sector, where smaller companies like Kronos Bio are acquired by larger entities or private equity firms (Concentra Biosciences, LLC) to integrate assets, pipelines, or market positions. Such mergers are common strategies for growth, portfolio expansion, or achieving synergies in the highly competitive and capital-intensive biotech industry. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech mergers to bridge valuation gaps, allowing sellers to participate in potential future upside from specific assets or milestones.

Comparison to Industry Standards

• The use of a tender offer followed by a short-form merger is a standard acquisition mechanism in the U.S. market, particularly for public companies.
• The inclusion of Contingent Value Rights (CVRs) in the deal structure is also a common practice in biotech and pharmaceutical acquisitions, similar to deals involving companies like Celgene (acquired by Bristol-Myers Squibb, which included CVRs tied to drug approvals) or Allergan (acquired by AbbVie, also involving CVRs).
• The specific offer price of $0.57 per share in cash, combined with CVRs, would need to be compared to recent acquisition multiples for similar-stage biotech companies with comparable pipelines or market positions to assess its competitiveness, but this document does not provide enough information for such a detailed comparison.

Stakeholder Impact

• Shareholders: Former Kronos Bio shareholders received $0.57 per share in cash and one non-transferable Contingent Value Right (CVR) for each share, providing immediate liquidity and potential future upside.
• Option Holders: Option holders, such as the reporting person, whose exercise prices were above the cash offer price, had their options cancelled for no cash consideration, receiving only CVRs for the underlying shares.
• Employees: While not explicitly stated, mergers often lead to organizational restructuring and potential changes for employees of the acquired entity.

Next Steps

• Former Kronos Bio shareholders will await potential future payments or milestones related to the Contingent Value Rights (CVRs).

Key Dates

Keywords

Kronos Bio, KRON, Concentra Biosciences, Merger, Acquisition, SEC Form 4, Stock Options, Contingent Value Rights, CVR, Tender Offer, Beneficial Ownership, Director, Katherine V. Stultz